Ipragliflozin
As of the edition of 20 October 2026, Ipragliflozin is a small molecule: stopped in 2018; acts on SLC5A2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Small molecule
- Registered trials
- 54, 2 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Pregnancy and women's health; Urinary and reproductive; Digestive system; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC5A2 | Sodium/glucose cotransporter 2 | P31639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 1 | 0 |
| Phase 1 | 22 | 22 | 0 | 0 |
| Phase 2 | 5 | 5 | 0 | 0 |
| Phase 3 | 17 | 16 | 0 | 1 |
| Phase 4 | 6 | 5 | 0 | 1 |
| All trials | 54 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Astellas | Lead sponsor of trials | 2006 to now |